RÉSUMÉ
Malignant melanoma presents a significant therapeutic challenge to clinicians with characteristics of early metastasis, rapid development, poor prognosis and high mortality. Many therapies for metastatic melanoma are limited by these characteristics. With the development of immunotherapy mechanism for malignant melanoma, a large number of antibody agents for the treatment of malignant melanoma entered the clinical trials. To our great delight, the new drugs of pembrolizumab and nivolumab have been approved by FDA in 2014 after successfully passing phase III clinical trial, which bring a chance of survival to patients with unresectable or metastatic advance melanoma. This review briefly discusses recent development and advances of anti-PD-L1/PD-1 antibody drugs against melanoma.